FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2954156724> ?p ?o ?g. }

• W2954156724 abstract "TPS7569 Background: Progress in genome technology allows analysis of previously completed trials to identify patients subgroups potentially benefiting from therapy. Enzastaurin is a potent inhibitor of protein kinase C beta (PKC- b) and suppresses the phosphoinositide 3-kinase (PI3K)/AKT pathway. The safety and efficacy of Enzastaurin has been tested in more than 60 clinical trials including 2 major studies in DLBCL: (1) PRELUDE (A phase III maintenance trial of Enzastaurin vs Placebo, N=758) ( Crump, 2016), and (2) S028 (A randomized phase II study of Enzastaurin/R-CHOP vs R-CHOP in frontline intermediate/high-risk DLBCL, N=101) ( Hainsworth, 2016). DNA samples extracted from blood of patients from PRELUDE were retrospectively genotyped using whole genome SNP arrays. From the genome wide screening a novel genetic biomarker, DGM1, was identified showing high correlation with response to Enzastaurin treatment ( Luo, ASH 2018). Importantly, these findings were replicated in the phase II S028 study. In the S028 study the hazard ratio (HR) for OS in high-risk (IPI ≥ 3) DGM1 positive (+) patients who received Enzastaurin/R-CHOP was 0.28 (0.1-0.81) when compared to subjects who received R-CHOP, a benefit favoring Enzastaurin (p=0.018). These data suggest that addition of Enzastaurin to R-CHOP may significantly improve outcome in frontline high-risk DGM1 (+) DLBCL. The ENGINE study was initiated to validate this finding in a prospective study. Methods: Adult patients must have untreated CD20+ DLBCL, IPI ≥ 3. Patients are randomized 1:1 to Enzastaurin/R-CHOP or Placebo/R-CHOP for 6 cycles during combination phase. Each subject’s treatment assignment will be unblinded after response assessment at the end of the combination phase. Subjects randomized to the investigational arm who have a complete or partial response will have the option to continue in the single agent phase to receive Enzastaurin for up to 2 additional years. The study intends to enroll approximately 235 patients with primary endpoint of OS in DGM1 (+) patients. The study is ongoing with 51 sites open in the US and China. As of 22 Jan 2019, 70 patients have been randomized. Clinical trial information: NCT03263026." @default.
• W2954156724 created "2019-07-12" @default.
• W2954156724 creator A5002126535 @default.
• W2954156724 creator A5005791381 @default.
• W2954156724 creator A5030040961 @default.
• W2954156724 creator A5032067232 @default.
• W2954156724 creator A5035978871 @default.
• W2954156724 creator A5049573435 @default.
• W2954156724 creator A5061713890 @default.
• W2954156724 creator A5071798264 @default.
• W2954156724 creator A5088459737 @default.
• W2954156724 creator A5088587277 @default.
• W2954156724 date "2019-05-20" @default.
• W2954156724 modified "2023-10-05" @default.
• W2954156724 title "ENGINE: Phase III randomized study of enzastaurin/R-CHOP versus placebo/R-CHOP in frontline high-risk diffuse large B-cell lymphoma patients with novel genomic biomarker DGM1." @default.
• W2954156724 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.tps7569" @default.
• W2954156724 hasPublicationYear "2019" @default.
• W2954156724 type Work @default.
• W2954156724 sameAs 2954156724 @default.
• W2954156724 citedByCount "0" @default.
• W2954156724 crossrefType "journal-article" @default.
• W2954156724 hasAuthorship W2954156724A5002126535 @default.
• W2954156724 hasAuthorship W2954156724A5005791381 @default.
• W2954156724 hasAuthorship W2954156724A5030040961 @default.
• W2954156724 hasAuthorship W2954156724A5032067232 @default.
• W2954156724 hasAuthorship W2954156724A5035978871 @default.
• W2954156724 hasAuthorship W2954156724A5049573435 @default.
• W2954156724 hasAuthorship W2954156724A5061713890 @default.
• W2954156724 hasAuthorship W2954156724A5071798264 @default.
• W2954156724 hasAuthorship W2954156724A5088459737 @default.
• W2954156724 hasAuthorship W2954156724A5088587277 @default.
• W2954156724 hasConcept C126322002 @default.
• W2954156724 hasConcept C142724271 @default.
• W2954156724 hasConcept C143998085 @default.
• W2954156724 hasConcept C204787440 @default.
• W2954156724 hasConcept C207103383 @default.
• W2954156724 hasConcept C27081682 @default.
• W2954156724 hasConcept C2778559949 @default.
• W2954156724 hasConcept C2779338263 @default.
• W2954156724 hasConcept C2779725641 @default.
• W2954156724 hasConcept C44249647 @default.
• W2954156724 hasConcept C71924100 @default.
• W2954156724 hasConcept C98274493 @default.
• W2954156724 hasConceptScore W2954156724C126322002 @default.
• W2954156724 hasConceptScore W2954156724C142724271 @default.
• W2954156724 hasConceptScore W2954156724C143998085 @default.
• W2954156724 hasConceptScore W2954156724C204787440 @default.
• W2954156724 hasConceptScore W2954156724C207103383 @default.
• W2954156724 hasConceptScore W2954156724C27081682 @default.
• W2954156724 hasConceptScore W2954156724C2778559949 @default.
• W2954156724 hasConceptScore W2954156724C2779338263 @default.
• W2954156724 hasConceptScore W2954156724C2779725641 @default.
• W2954156724 hasConceptScore W2954156724C44249647 @default.
• W2954156724 hasConceptScore W2954156724C71924100 @default.
• W2954156724 hasConceptScore W2954156724C98274493 @default.
• W2954156724 hasLocation W29541567241 @default.
• W2954156724 hasOpenAccess W2954156724 @default.
• W2954156724 hasPrimaryLocation W29541567241 @default.
• W2954156724 hasRelatedWork W1951491830 @default.
• W2954156724 hasRelatedWork W2022166786 @default.
• W2954156724 hasRelatedWork W2053806269 @default.
• W2954156724 hasRelatedWork W2075609648 @default.
• W2954156724 hasRelatedWork W2334374063 @default.
• W2954156724 hasRelatedWork W2971304898 @default.
• W2954156724 hasRelatedWork W3008181062 @default.
• W2954156724 hasRelatedWork W3162065781 @default.
• W2954156724 hasRelatedWork W417977356 @default.
• W2954156724 hasRelatedWork W4386281991 @default.
• W2954156724 isParatext "false" @default.
• W2954156724 isRetracted "false" @default.
• W2954156724 magId "2954156724" @default.
• W2954156724 workType "article" @default.